![]() |
![]() |
![]() |
|
![]() |
2017 Publication |
![]() |
|
Temozolomide in the Era of Precision Medicine.
Cancer Res. 2017 Feb 15. [Epub ahead of print].
Phosphorylated fraction of H2AX as a measurement for DNA damage in cancer cells and potential applications of a novel assay.Plos One. 2017 Feb 3.
The NCI-60 Methylome and its Integration into CellMiner.
Cancer Res. 2017 Feb 1. pii: [Epub ahead of print].
Cytidine deaminase deficiency reveals new therapeutic opportunities against cancer.
Clin Cancer Res. 2017 Apr 15. pii: clincanres.0626.2017. [Epub ahead of print].
|
This web site is a development of the Genomics and Pharmacology Facility, Developmental Therapeutics Branch (DTB), Center for Cancer Research (CCR), National Cancer Institute (NCI). |
If you have questions or comments about this site, please send them to: webadmin@discover.nci.nih.gov. Please see our credits page and disclaimer for more information. |